Radiopharmaceutical Trials in Latin America: A Logistics Readiness Framework for Sponsors

Radiopharmaceutical and theranostics programs have accelerated globally, but their clinical execution has a unique constraint: you are not only running a trial — you are running a time-sensitive supply chain. In Latin America, that supply chain can be a competitive advantage when it is planned well, and a critical risk when it is treated as an afterthought.

This article offers a practical logistics readiness framework for sponsors planning radiopharmaceutical clinical trials in Latin America. The goal is to help clinical and operational leaders identify failure modes early and design a deployment plan that matches the physics, not just the protocol.

Why radiopharmaceutical logistics is different

Radiopharmaceutical trials have “hard” operational constraints: isotope half-life, radiation safety controls, qualified hot lab capacity, imaging standardization, and tightly coordinated shipment windows. In addition, sponsors may need to coordinate with multiple stakeholders — manufacturer, radiopharmacy, courier, customs brokers, hospital nuclear medicine teams, and regulators — where each handoff introduces risk.

Because of these constraints, a strong sponsor question is: Can we execute the chain reliably, repeatedly, and compliantly for every subject?

A logistics readiness framework (4 pillars)

Use the following four pillars to assess readiness before site activation.

Pillar 1: Isotope supply and contingency planning

• Primary supply route: Define the manufacturing source, batch release timing, and shipment windows that match enrollment cadence.
• Secondary route: Identify a backup route for disruptions (transport restrictions, manufacturing delays, flight changes).
• Buffer strategy: For short half-life isotopes, “buffer” often means operational flexibility (multiple shipment windows) rather than inventory.

Pillar 2: Regulatory and permit architecture

• Import permits and documentation: Confirm what must be approved before the first shipment, and what can be handled per-shipment.
• Labeling and chain-of-custody: Ensure labels, documentation, and custody logs satisfy both radiation safety and clinical trial requirements.
• Waste and radiation safety: Map disposal pathways and responsibilities with each site to avoid last-minute operational blocks.

Pillar 3: Site infrastructure and workflow maturity

• Hot lab capability: Validate equipment, personnel qualification, and SOPs for receipt, preparation, and administration.
• Scheduling discipline: Radiopharmaceutical administration is scheduling-sensitive. Sites need reliable slot control and patient preparedness workflows.
• Adverse event readiness: Ensure emergency procedures and escalation pathways are documented and rehearsed.

Pillar 4: Imaging, dosimetry, and data standardization

• Imaging protocol consistency: Standardize acquisition parameters and timing relative to administration.
• Calibration and QA: Establish calibration schedules and quality checks to reduce inter-site variability.
• Data transfer and review: Define secure transfer pathways, central reads (if used), and turnaround expectations.

Common failure modes — and how to prevent them

• Enrollment outpaces supply planning: Align recruitment targets to realistic shipment cadence and site throughput.
• Customs and documentation surprises: Create country-specific shipment playbooks and run a “first shipment rehearsal.”
• Inconsistent imaging: Use standardized checklists and training, and consider centralized QA early.
• Site capability overestimation: Validate the workflow in practice, not only on paper. A site can be clinically excellent and still operationally unready for radiopharmaceutical constraints.

FAQ

1) What should we assess first when choosing Latin American countries for radiopharmaceutical trials?
Start with isotope availability routes, hot lab capacity, and the country’s ability to support compliant import and radiation safety workflows. If those are weak, other advantages will not compensate.

2) Are logistics risks higher in Latin America than in the U.S. or EU?
They are different. Risks often relate to cross-border shipment orchestration and variability in infrastructure by site. With the right planning and experienced operators, sponsors can build reliable execution pathways.

3) How do we prevent schedule failures due to isotope half-life constraints?
Design your operational plan around the isotope clock: confirmed shipment windows, controlled scheduling, backup routes, and rapid communication workflows across all parties.

Bottom line: Radiopharmaceutical clinical trials reward operational maturity. Sponsors that treat logistics as a core part of trial design — not a downstream task — can unlock faster, more reliable execution across Latin America.